home About Us People Portfolio News Contact Us Fund II Investor Login » Fund III Investor Login » Fund IV Investor Login »

Avinger Inc.

$45 million

Medical Device
Cardiovascular

Jun15
2015
Avinger Announces Presentations by Key Opinion Leaders and Live Case Transmission at LINC »

Jan14
2015
Avinger Announces Closing of $7.6 Million Registered Direct Offering »

Jan11
2015
Avinger Announces 510(k) Clearance for Lightbox 3 Next-Generation Imaging Console »

Aug9
2015
Avinger Announces 510(k) Filing for New Lightbox 3 Imaging Console »

Jul6
2015
Avinger Announces 510(k) Filing for New Pantheris In-Stent Restenosis Indication »

May25
2015
Avinger Announces Issuance and Allowance of Seven U.S. Patents »

Apr21
2015
New Publications Highlight Clinical Benefits of Avinger PAD Therapies »

Apr8
2015
Avinger Provides Update on Tigereye(TM) Commercial Launch »

Dec4
2015
Avinger Expands Tigereye(TM) Limited Launch »

Dec1
2015
Avinger Receives Nasdaq Extension, Recommends Stockholders Vote FOR All Proxy Proposals »

Redwood City, CA / ACCESSWIRE / December 1, 2020 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first-ever image-guided, catheter-based system for the diagnosis and treatment of Peripheral Artery Disease (PAD), today announced the company has received an extension until May 19, 2021 to regain compliance with the Nasdaq minimum bid price requirement for continued listing. The company previously had until November 20, 2020 to regain compliance, and received its extension notice on November 24, 2020.

 

To ensure Avinger will successfully resolve its minimum bid price requirement, either through organic growth in its stock price or via a reverse stock split, Avinger has included a proposed authorization for the Board of Directors to effect a reverse stock split at a ratio not less than 1-for-5 and not greater than 1-for-20 to maintain Avinger's Nasdaq listing.

 

Avinger's management and Board of Directors recommend that stockholders eligible to vote at the Company's upcoming annual meeting vote FOR all proposals, including the reverse stock split proposal.

 

Both Institutional Shareholder Services (ISS) and Glass Lewis, two leading proxy advisory services firms, have recommended voting FOR the proposed reverse stock split.

 

"We recommend that stockholders immediately vote FOR all proxy proposals to ensure that Avinger has every tool available to maintain its Nasdaq listing," said Jeff Soinski, Avinger's President and CEO. "Should a reverse stock split be needed to maintain our listing, and stockholders do not vote in favor of the authorization at the annual meeting on December 10, Avinger would need to hold another meeting within just three to four months at significant cost, diverting personnel and cash resources from our growth plans for 2021 and beyond. We believe that voting FOR all proposals at the regularly scheduled meeting on December 10 avoids this needless time and expense. Further, we believe that voting FOR the proposals now addresses what would otherwise be ongoing uncertainty around our listing status."

 

"Avinger has made significant progress in 2020, despite the global COVID-19 pandemic," continued Soinski. "While it has been a challenging year, we believe our third quarter results showed solid progress, including FDA clearance of our new Tigereye™ CTO catheter and the launch of 10 new user sites. During 2020, we took steps to fund our growth capital needs for 2020 and 2021, positioning Avinger with a strong balance sheet to support our strategic initiatives. We have also maintained a number of the operating expense cuts enacted earlier in 2020, emerging a leaner, more efficient growth business ready for the year ahead. With three best-in-class products, our new L300 Lightbox development advancing well and exciting clinical studies to continue documenting our patient outcomes, 2021 should be a transformative year for Avinger. We believe that a vote FOR the reverse split proposal reduces future administrative costs and is in the best interest of all shareholders."

 

Stockholders of record as of the close of business on October 20, 2020 are entitled to vote in the annual meeting. The fastest and easiest way to vote is by telephone or via the internet. Instructions on how to vote the shares by telephone or Internet are provided on the proxy card enclosed with materials previously mailed to you.

 

Alternatively, stockholders may be able to vote by phone by calling Avinger's proxy solicitation firm, Morrow Sodali LLC at 1-877-787-9239. Avinger urges all stockholders to read the full proxy statement, which has been filed with the Securities and Exchange Commission at www.sec.gov, can be obtained at no charge by calling our proxy solicitation firm at the number above, or can be obtained online at https://irdirect.net/AVGR/sec_filings.

 

About Avinger, Inc.

 

Avinger is a commercial-stage medical device company that designs and develops the first and only image-guided, catheter-based system for the diagnosis and treatment of patients with Peripheral Artery Disease (PAD). PAD is estimated to affect over 12 million people in the U.S. and over 200 million worldwide. Avinger is dedicated to radically changing the way vascular disease is treated through its Lumivascular platform, which currently consists of the Lightbox imaging console, the Ocelot family of chronic total occlusion (CTO) catheters, and the Pantheris® family of atherectomy devices. Avinger is based in Redwood City, California. For more information, please visit www.avinger.com.

 

Forward-Looking Statements

 

This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. These forward-looking statements include statements regarding our future performance. Such statements are based on current assumptions that involve risks and uncertainties that could cause actual outcomes and results to differ materially. These risks and uncertainties, many of which are beyond our control, include our dependency on a limited number of products; the resource requirements related to Pantheris, Tigereye and our Lightbox imaging console; the outcome of clinical trial results; as well as the other risks described in the section entitled "Risk Factors" and elsewhere in our Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 6, 2020, and subsequent Form 10-Qs. These forward-looking statements speak only as of the date hereof and should not be unduly relied upon. Avinger disclaims any obligation to update these forward-looking statements.

 

Investor Contact:

 

Mark Weinswig
Chief Financial Officer
Avinger, Inc.
(650) 241-7916
ir@avinger.com

 

Matt Kreps
Darrow Associates Investor Relations
(214) 597-8200
mkreps@darrowir.com

 

SOURCE: Avinger, Inc.

Sep11
2015
Avinger Receives FDA Clearance of Ocelaris Next Generation Image-guided CTO Crossing System »

Apr30
2015
Avinger Closes $3.15 Million Equity Offering »

Aug16
2015
Avinger, Inc. Announces Closing of Public Offering of Common Stock and Underwriters’ Full Exercise of Option to Purchase Additional Shares »

Jun15
2015
Avinger, Inc. Announces Drawdown of $10 Million Under Term Loan Facility with CRG »

Dec1
2015
Avinger Announces Filing of 510(k) Application for Enhanced Version of Pantheris(TM) »

Nov2
2015
Avinger Successfully Completes VISION IDE Trial for Pantheris(TM) »

Oct14
2015
Avinger, Inc. Receives FDA 510(k) Clearance for Pantheris(TM) »

Sep23
2015
Avinger, Inc. Secures Up To $55M in Financing from CRG »